Vtesse Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $200M

Vtesse General Information

Description

Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatments, includes treatment for rare disease Niemann-Pick Disease Type C (NPC), enabling patients with NPC and other lysosomal storage diseases to get treated. It also offers information, resources and support that can be used to better understand NPC and to cope with its impact on lives.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Information Services (B2C)
Corporate Office
  • 910 Clopper Road
  • Suite 220 South
  • Gaithersburg, MD 20878
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vtesse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 03-Apr-2017 $200M 0000 00000 Completed Startup
2. Early Stage VC (Series A) 25-Jul-2016 0000 0000 000.00 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view Vtesse’s complete valuation and funding history, request access »

Vtesse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view Vtesse’s complete cap table history, request access »

Vtesse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatmen
Drug Discovery
Gaithersburg, MD
10 As of 2017
0000
0000 0000-00-00
000000&0 0000

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Clarksville, MD
0 As of 0000
00.000
00000000000

000000

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000 000000000
New York, NY
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vtesse Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
Neurogene Formerly VC-backed New York, NY 00 00000 000000000 00000
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
Axial Therapeutics Venture Capital-Backed Woburn, MA 00 00000 0000000000 0 00000
CuraSen Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 14 competitors. Get the full list »

Vtesse Patents

Vtesse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016276774-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 0000000000
EP-3307278-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 0000000000
EP-3307278-A4 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 0000000000
US-20160361345-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 0000000000
CA-2988529-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 A61K31/724
To view Vtesse’s complete patent history, request access »

Vtesse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vtesse Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Venture Capital Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Cydan Accelerator/Incubator Minority 000 0000 000000 0
Lundbeckfonden BioCapital Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »